CONFERENCE. Diabetes mellitus: magnitude of the problem, its pathophysiology, diagnosis and treatment
DOI:
https://doi.org/10.47196/diab.v57i3Sup.694Keywords:
diabetes, pathophysiology, diagnosis, treatmentAbstract
I will start by noting what Frederick Grant Banting mentioned in his Nobel Prize acceptance speech for the discovery of insulin: “The hormone is not a cure, it is a treatment that keeps people alive, and if we want to prevent long-term complications of diabetes mellitus (DM), we need to understand how insulin is normally secreted and what is failing in that disease."
For his part, another great diabetologist, Elliot Joslin, in 1925 in his Treatise on Diabetes, mentioned that: "There should be an education program that would explain to the community the importance of diet, combat a sedentary lifestyle to avoid obesity and prevent the appearance of DM, and also show the role of these measures in the control and treatment of this disease”. But it ended with a lapidary phrase for the union: this type of program should begin its dissemination among doctors.
However, somehow the doubt of its benefit was generated, and in 2009 the Cochrane Foundation1 concluded that the individual education of people with DM2 only shows benefits when the glycosylated hemoglobin (HbA1c) is greater than 8% and new evidence is needed that demonstrate the benefits of education, especially in the long term1. This last sentence is especially dedicated to those of us who are dedicated to the education of people with DM. But without a doubt today we can affirm, paraphrasing the tango Cambalache by Enrique Santos Discépolo, that the phrases of Banting and Joslin were true in 1925 and in 2022 as well.
References
I. Duke SA, Colagiuri S, Colagiuri R. Individual patient education for people with type 2 diabetes mellitus. Cochrane Database Syst Rev 2009 Jan 21;1. doi: 10.1002/14651858.CD005268.pub2.
II. Gerich JE, Meyer C, Woerle HJ, Stumvoll M. Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care 2001;24:382-91.
III. Wilding JP. The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium-glucose co-transporter 2 inhibitors. Metabolism 2014;63:1228-37.
IV. Wahren J, Ekberg K. Splanchnic regulation of glucose production. Annual Review of Nutrition 2007; 27:329-345.
V. Kyoung-Jin Oh, et al. CREB and FoxO1: two transcription factors for the regulation of hepatic gluconeogénesis. BMB Rep 2013;46:567.
VI. Gagliardino JJ, de la Hera M, Siri F; Grupo de Investigación de la Red QUALIDIAB. Evaluación de la calidad de la asistencia al paciente diabético en América Latina. Rev Panam Salud Publica/Pan Am J Public Health 2001;10(5).
VII. Elgart JF, Asteazarán S, De La Fuente JL, Camillucci C, Brown JB, Gagliardino JJ. Direct and indirect costs associated to type 2 diabetes and its complications measured in a social security institution of Argentina. Int J Public Health 2014; 59:851-7.
VIII. Olivera EM, Pérez-Duhalde E, Gagliardino JJ. Costs of temporary and permanent disability induced by diabetes. Diabetes Care 1991;14:593-596.
IX. Elgart JF, Caporale JE, Asteazarán S, De La Fuente JL, Camilluci C, Brown JB, González CD, Gagliardino JJ. Association between socioeconomic status, type 2 diabetes, and its chronic complications in Argentina. Diabetes Research and clinical practice 2014;104:241-247.
X. Herman WH, Ye W, Griffin SJ, et al. Early detection and treatment of type 2 diabetes reduce cardiovascular morbidity and mortality. A simulation of the results of the Anglo-Danish-Dutch Study of Intensive Treatment in People With Screen-Detected Diabetes in Primary Care (ADDITION-Europe). Diabetes Care 2015;38(8):1449-55.
XI. Gagliardino JJ, Elgart J, Forti L, et al. Type 2 diabetes: prescription patterns and treatment outcomes of IDMPS survey in Argentina. Diabetes Res Clin Pract 2019; 153:86-92.
XII. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004 Jul;27(7):1535-40.
XIII. Lachin JM, Genuth S, Cleary P, Davis MD, Nathan DM. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000 Feb 10;342(6):381-9.
XIV. Gagliardino JJ, Elgart J, Ré M, et al. Diabetes primary prevention program: new insights from data analysis of recruitment period. Diabetes Metab Res Rev 2018 Jan;34(1).
XV. Gerstein HC, Santaguida P, Raina P, et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract 2007 Dec;78(3):305-12.
XVI. Butler AE, Bonner-Weir S, Rizza RA, Butler PC, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003 Jan;52(1):102-10.
XVII. Rütti S, Ehses JA, Sibler RA, Prazak R, Rohrer L. Low- and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta-cells. Endocrinology 2009 Oct;150(10):4521-30.
XVIII. Gagliardino JJ, Salazar MR, Espeche WG, et al. Arterial stiffness: its relation with prediabetes and metabolic syndrome and possible pathogenesis. J Clin Med 2021 Jul 23;10(15):3251.
XIX. Lean MEJ, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomized trial. The Lancet 2018;391(10120):541-551.
XX. Cnop M, Hughes SJ, Igoillo-Esteve M, Hoppa MB, et al. The long lifespan and low turnover of human islet beta cells estimated by mathematical modelling of lipofuscin accumulation. Diabetologia 2010 Feb;53(2):321-30.
XXI. Zanone MM, Favaro E, Camussi G, et al. From endothelial to beta cells: insights into pancreatic islet microendothelium. Curr Diabetes Rev 2008 Feb;4(1):1-9.
XXII. Román C, Maiztegui B, Del Zotto H, Gagliardino JJ, Flores LE. INGAP-PP effects on β-cell mass and function are related to its positive effect on islet angiogenesis and VEGFA production. Molecular and Cellular Endocrinology 2018;470:269-280.
XXIII. Maiztegui B, Roman C, Barbosa H, Boschero C, Gagliardino JJ. Role of islet glucokinase, glucose metabolism, and insulin pathway in the enhancing effect of islet neogenesis-associated protein upon glucose-induced insulin secretion. Pancreas 2015;44(6):959-966.
XXIV. Dungan KM, Buse JB, Ratner RE. Effects of therapy in type 1 and type 2 diabetes mellitus with a peptide derived from islet neogenesis associated protein (INGAP). Diabetes Metab Res Rev 2009 Sep;25(6):558-65.
XXV. Lynn S, Espinosa-Silva YR, Diambra L, McCarthy AN, Liping L, Ru B, Román C, Maiztegui B, Flores LE, Gagliardino JJ. A new analog of islet neogenesis associated protein with higher structural and plasma stability. J Biomol Struct Dyn 2021 Feb;39(3):766-776.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 on behalf of the authors. Reproduction rights: Argentine Diabetes Society
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
